Assessment of Potential Impact of Demographic and Baseline Disease Characteristics on Rifaximin Monotherapy versus Lactulose Combination Therapy for the Prevention of Overt Hepatic Encephalopathy (OHE) Recurrence

被引：1
|
作者：
Flamm, Steven [1 ]
Mullen, Kevin [2 ]
Heimanson, Zeev [3 ]
Sanyal, Arun [4 ,5 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Metrohlth Med Ctr, Cleveland, OH USA
[3] Salix Pharmaceut, Bridgewater, NJ USA
[4] Virginia Commonwealth Univ, Richmond, VA USA
[5] McGuire VA Med Ctr, Richmond, VA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2017年 / 112卷
关键词：
D O I：
10.14309/00000434-201710001-00876
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
875
引用
收藏
页码：S494 / S494
页数：1
相关论文
共 14 条
  • [1] Impact of Rifaximin Monotherapy Versus Rifaximin and Lactulose Combination Therapy on Quality of Life in Patients With a History of Overt Hepatic Encephalopathy (OHE)
    Sanyal, Arun J.
    Heimanson, Zeev
    Israel, Robert
    Mullen, Kevin D.
    Flamm, Steven L.
    HEPATOLOGY, 2017, 66 : 268A - 268A
  • [2] Efficacy and Safety of Rifaximin Monotherapy Versus Lactulose Combination Therapy for the Prevention of Overt Hepatic Encephalopathy (HE) Recurrence
    Sanyal, Arun J.
    Hassanein, Tarek I.
    Kayali, Zeid
    Kang, Robert
    Wolf, Ray A.
    Mullen, Kevin D.
    HEPATOLOGY, 2016, 64 : 130A - 131A
  • [3] Genomic Characterization of Stool Microbiota With Rifaximin Monotherapy Versus Lactulose Combination Therapy for Prevention of Overt Hepatic Encephalopathy (HE) Recurrence
    Dupont, Herbert L.
    Hassanein, Tarek I.
    Sanyal, Arun J.
    Wolf, Ray A.
    Mullen, Kevin D.
    HEPATOLOGY, 2016, 64 : 720A - 721A
  • [4] RIFAXIMIN AND LACTULOSE COMBINATION THERAPY VERSUS LACTULOSE ALONE FOR PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: A POOLED ANALYSIS OF TWO RANDOMIZED TRIALS
    Bajaj, Jasmohan S.
    Heimanson, Zeev
    Israel, Robert
    GASTROENTEROLOGY, 2019, 156 (06) : S560 - S560
  • [5] RIFAXIMIN PLUS LACTULOSE IS MORE EFFICACIOUS THAN LACTULOSE ALONE FOR THE PREVENTION OF OVERT HEPATIC ENCEPHALOPATHY (OHE) IN PATIENTS WITH OR WITHOUT ASCITES
    Kowdley, Kris V.
    Reau, Nancy
    Pyrsopoulos, Nikolaos T.
    Allen, Christopher
    Heimanson, Zeev
    Sanyal, Arun J.
    GASTROENTEROLOGY, 2023, 164 (06) : S1327 - S1327
  • [6] EFFICACY OF RIFAXIMIN VERSUS LACTULOSE FOR REDUCING THE RECURRENCE OF OVERT HEPATIC ENCEPHALOPATHY AND HOPITALIZATIONS IN CIRRHOSIS
    Irimia, Roxana
    Trifan, Anca
    MEDICAL-SURGICAL JOURNAL-REVISTA MEDICO-CHIRURGICALA, 2012, 116 (04): : 1021 - 1027
  • [7] Improved Outcomes in Hepatic Encephalopathy Using Rifaximin Monotherapy Compared to Rifaximin and Lactulose Combination Therapy
    Neff, Guy W.
    Flamm, Steven L.
    Mullen, Kevin D.
    Barrett, Andrew C.
    Bortey, Enoch
    Paterson, Craig
    Forbes, William P.
    GASTROENTEROLOGY, 2013, 144 (05) : S451 - S451
  • [8] Rifaximin Monotherapy Is More Effective Than Lactulose Monotherapy for Reducing the Risk of Overt Hepatic Encephalopathy (OHE) Recurrence and All-Cause Mortality: An Analysis of Two Randomized Trials
    Bajaj, Jasmohan S.
    Rahimi, Robert S.
    Allen, Christopher
    Heimanson, Zeev
    Israel, Robert J.
    Kowdley, Kris V.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1210 - S1210
  • [9] RIFAXIMIN PLUS LACTULOSE VERSUS LACTULOSE ALONE FOR REDUCING THE RISK OF OVERT HEPATIC ENCEPHALOPATHY RECURRENCE: A POOLED SUBGROUP ANALYSIS
    Sanyal, Arun J.
    Brown, Robert S., Jr.
    Sundaram, Vinay
    Heimanson, Zeev
    Israel, Robert J.
    Bajaj, Jasmohan S.
    HEPATOLOGY, 2022, 76 : S1186 - S1187
  • [10] Rifaximin Plus Lactulose Is More Efficacious Than Lactulose Alone for Risk Reduction of Overt Hepatic Encephalopathy (OHE) Recurrence: A Subgroup Analysis by Viral or Alcohol Cirrhosis Etiology
    Bajaj, Jasmohan
    Sanyal, Arun
    Sundaram, Vinay
    Frenette, Catherine
    Heimanson, Zeev
    Israel, Robert
    Brown, Robert S.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S570 - S570
12